Compare TRDA & LCNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRDA | LCNB |
|---|---|---|
| Founded | 2016 | 1877 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.6M | 223.1M |
| IPO Year | 2021 | 1999 |
| Metric | TRDA | LCNB |
|---|---|---|
| Price | $6.46 | $19.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $21.00 | N/A |
| AVG Volume (30 Days) | ★ 345.9K | 33.1K |
| Earning Date | 05-08-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 5.43% |
| EPS Growth | N/A | ★ 68.04 |
| EPS | N/A | ★ 0.31 |
| Revenue | ★ $25,421,000.00 | $6,445,000.00 |
| Revenue This Year | $39.97 | $8.50 |
| Revenue Next Year | $50.80 | $3.66 |
| P/E Ratio | ★ N/A | $63.90 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.93 | $14.11 |
| 52 Week High | $16.45 | $20.62 |
| Indicator | TRDA | LCNB |
|---|---|---|
| Relative Strength Index (RSI) | 40.49 | 63.56 |
| Support Level | $5.75 | $16.16 |
| Resistance Level | $7.02 | N/A |
| Average True Range (ATR) | 0.46 | 0.71 |
| MACD | -0.06 | 0.17 |
| Stochastic Oscillator | 13.87 | 63.31 |
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections, and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.